Dataset from A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006704
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
创建时间：
2026-03-25
